1Cannon CP, Harrington RA, James S, et al. Comparison ofticagrelor with clopidogrel in patients with a planned invasivestrategy for acute coronary syndromes ( PLATO) : a randomiseddouble-blind study. Lancet, 2010, 375: 283-293.
2Bonaca MP,Wiviott SD, Braunwald E,et al. American Collegeof Cardiology/American Heart Association/European Society ofCardiology/World Heart Federation universal definition ofmyocardial infarction classification system and the risk ofcardiovascular death : observations from the TRITON-TIMI 38trial (Trial to Assess Improvement in Therapeutic Outcomes byOptimizing Platelet Inhibition With Prasugrel-Thrombolysis inMyocardial Infarction 38). Circulation, 2012, 125 : 577-583.
3ESC Guidelines for the management of acute myocardialinfarction in patients presenting with ST-segment elevation : TheTask Force on the management of ST-segment elevation acutemyocardial infarction of the European Society of Cardiology(ESC). ESC Committee for Practice Guidelines. Eur Heart J,2012,Aug 24 (online ).
4Jneid H, Anderson JL, Wright RS,et al. 2012 ACCF/AHAFocused Update of the Guideline for the Management of PatientsWith Unstable Angina/Non-ST-Elevation Myocardial Infarction(Updating the 2007 Guideline and Replacing the 2011 FocusedUpdate) : A Report of the American College of CardiologyFoundation/American Heart Association Task Force on PracticeGuidelines. J Am Coll Cardiol, 2012,60: 645-681.
5Mehta SR, Tanguay JF, Eikelboom JW’ et al. CURRENT-OASIS7 trial investigators. Double-dose versus standard-dose clopidogreland high-dose versus low-dose aspirin in individuals undergoingpercutaneous coronary intervention for acute coronary syndromes(CURRENT-OASIS 7): a randomised factorial trial. Lancet,2010,376: 1233-1243.
6Thiele H,Wdhrle J, Hambrecht R, et al. Intracoronary versusintravenous bolus abciximab during primary percutaneouscoronary intervention in patients with acute ST-elevationmyocardial infarction : a randomised trial. Lancet, 2012,379 ?923-931.
7Levine GN,Bates ER,Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Aimport of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelinesand the Society for Cardiovascular Angiography and Interventions.J Am Coll Cardiol, 2011,58: e44-e122.
8Stone GW,Maehara A, Witzenbichler B,et al. INFUSE-AMIInvestigators. Intracoronary abciximab and aspirationthrombectomy in patients with large anterior myocardialinfarction: the INFUSE-AMI randomized trial. JAMA, 2012,307: 1817-1826.
9Kastrati A, Neumann FJ, Schulz S,et al. ISAR-REACT 4 TrialInvestigators. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med, 2011, 365 :1980-1989.
10Mega JL,Braunwald E,Wiviott SD, et al. ATLAS ACS 2-TIMI51 Investigators. Rivaroxaban in patients with a recent acutecoronary syndrome. N Engl J Med, 2012, 366: 9-19.
3Uehiyama S,Yamazaki M, HaraY, et al. Alterations of platelet, coagulation, and fibrinolysis markers in patients with acute ischemic stroke [ J]. Semin Thromb Hemost, 1997, 23 : 535- 541.
4EPILOG Investigators. Platelet glyeoproteinⅡH b/Ⅲ a receptor blockade and low-dose heparin during pereutaneous coronary revaseularization [J]. Med, 1997, 336: 1689-1696.
5Antithrombotic Trialists' Collaboration. Collaborative meta- analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [J]. BMJ, 2002, 324: 71-86.
6Barrab6s JA, Inserte J, Mirabet M, et al. Antagonism of P2Y12 or GP Ⅱ b/Ⅲ a receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts [ J ]. Thromb Haemost, 2010, 104: 128-135.
